Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target.

International journal of molecular sciences - 25 Aug 2021

Jung Hyojik, Bae Kieun, Lee Ja Young, Kim Jung-Hyun, Han Hyun-Jung, Yoon Hun-Young, Yoon Kyong-Ah

Abstract excerpt

Transitional cell carcinoma (TCC) is the most common malignant tumor of the canine urinary tract and tends to have a poor prognosis due to its invasive potential. Recent studies have reported that up to 80% of canine urothelial carcinoma has the BRAF V595E mutation, which is homologous to the human V600E mutation. Activating the BRAF mutation is an actionable target for developing effective therapeutic agents...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Transitional Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Culture Techniques

Share to Proto-Oncogene Proteins B-raf

Share to Sorafenib

Share to Urologic Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 34502061
DOI: 10.3390/ijms22179151
PMCID: PMC8430554

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target.PMID 34502061Read ↗

Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.Semantic proximity Read ↗

Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib).Semantic proximity Read ↗

Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test.Semantic proximity Read ↗

Establishment and characterization of urothelial carcinoma cell lines with and without BRAF mutation (V595E) in dogs.Semantic proximity Read ↗

BRAF Mutations in Canine Cancers.Semantic proximity Read ↗

Establishment of a BRAF V595E-mutant canine prostate cancer cell line and the antitumor effects of MEK inhibitors against canine prostate cancer.Semantic proximity Read ↗

Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma.Semantic proximity Read ↗

Proteomic Signatures of Vemurafenib Resistance in Canine Urothelial Carcinoma Harboring the BRAFV595E Mutation.Semantic proximity Read ↗

Effective detection of BRAFV595E mutation in canine urothelial and prostate carcinomas using immunohistochemistry.Semantic proximity Read ↗

Comparative Aspects of BRAF Mutations in Canine CancersSemantic proximity Read ↗

Management of transitional cell carcinoma of the urinary bladder in dogs: a review.Semantic proximity Read ↗

Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.